And they're off... Melanoma March 2016 begins!
29 February 2016
Melanoma March 2016 has kicked off with a bang! More than 300 people marched in Rockingham, WA and Devonport, TAS this weekend. It was great to see the melanoma community uniting to remember those who they have lost to melanoma, support those fighting the disease, and to raise money to support melanoma research.
Clinton Heal from MelanomaWA said of the Rockingham march “There were also many people there living with melanoma, and their family and friends were there to get behind them and the balloon release ceremony was a great way to both remember and rally together for all those touched by melanoma. With a large increase in participation compared to the 2015 event, we are excited for even bigger and better things for the 2017 Rockingham Melanoma March!”.
MIA’s Merrin Lavender attended the Devonport Melanoma March, which was the first march ever held in Tasmania. She said it was a great success and guest speakers include the founder of Melanoma TAS and the Deputy Premier of Tasmania, Jeremy Rockliff.
Thank you to everyone who came out to support Melanoma March and to our dedicated volunteers who have been tirelessly organsing these events.
This weekend marks just the beginning of a 6-week campaign for Melanoma March where Australia will unite against melanoma in 24 locations around the country. Register or make a donation to support Melanoma March today.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.